David Sinclair Plans Human Trials for Whole-Body Rejuvenation Drug in XPrize Competition

David Sinclair, a prominent longevity scientist and biologist at Harvard Medical School, has announced plans to initiate human trials for an oral "reprogramming" drug. This effort is being conducted as part of the XPrize Foundation's $101 million competition.

The competition offers cash awards to teams that can demonstrate a restoration of an individual's apparent age. The grand prize is allocated to any team that can show a relative improvement of 10 years or more after one year of treatment, as measured by advancements in immune, cognitive, and muscle function.

Sinclair confirmed that his team intends to provide an oral drug mixture to volunteers. The objective is to gather evidence for age restoration in humans, leveraging technology based on epigenetic reprogramming. This process involves resetting molecular controls on DNA, known as epigenetic marks, which influence a cell's metabolism and identity. This technology builds upon the discovery of genes capable of transforming adult cells into stem cells.

This new plan differs from Sinclair's company, Life Biosciences', recent human trial, which involves a gene therapy limited to treating eye conditions like glaucoma. Sinclair's current endeavor focuses on a drug designed for whole-body effects, enabling chemical reprogramming to mimic the effects of embryonic genes, with compounds capable of traveling throughout the bloodstream.

Some experts have expressed reservations, noting that the chemical reprogramming process, as used in laboratory settings, can be harsh and may not be highly effective. The exact composition of the drug candidate, code-named SL-100, remains confidential.

Sinclair's previous research includes published studies on "epigenetic age-reversal cocktails," which combined powerful chemicals with known supplements and commercially available medicines. James Clement, head of Betterhumans, an organization focused on life-extension studies, stated he is overseeing clinical trials for an oral reprogramming cocktail for Sinclair's XPrize team.

Sinclair's team is participating in the XPrize Healthspan Competition, which commenced in 2023. This competition is bankrolled by Saudi Arabia’s Hevolution. Executive Director Jamie Justice noted that if two teams achieve equivalent results, they would share the award.

According to MIT Technology Review, this trial, if it proceeds, would mark a significant development in the field of epigenetic reprogramming. (Source: MIT Technology Review)